Due to uncommon but occasionally fatal occurrences of blood clot formation, the Centers for Disease Control and Prevention advised U.S. residents on Thursday to pick one of two other certified COVID-19 vaccinations over the Johnson & Johnson vaccine, Reuters reports.
The CDC’s verdict was made after the Center’s Advisory Committee on Immunization decided via a unanimous vote in favor of the vaccinations developed by Moderna Inc and Pfizer/BioNTech over the Johnson&Johnson vaccine.
The J&J vaccination has been given to far fewer Americans than the other two immunizations. According to CDC statistics, out of over 200 million fully vaccinated persons in the United States, roughly 16 million got J&J’s shot.
Johnson&Johnson made a statement, in which the pharmaceutical company said that the health and safety of individuals who get their vaccination is its highest concern and that J&J is looking forward to collaborating with the CDC on the next steps.
Previous instances of thrombosis with thrombocytopenia syndrome (TTS), which encompasses blood clots and low platelet levels, have been described in J&J vaccination recipients. Women under the age of 50 had the greatest reported rates.
According to the CDC, the rate of such instances is greater than previously thought, in both men and women. The health agency detected more than 50 patients with TTS in the U.S., around 3.83 cases per million J&J dosages delivered.
According to the CDC, at least nine individuals have died in the United States as a result of blood clot formation.
Members of the panel also stated that J&J’s vaccine is less efficient than the other two approved shots in the prevention of the coronavirus.
A top J&J shot expert told the committee that the vaccine induces a powerful and long-lasting immune response with just one dose.
To induce immunity in patients, J&J’s vaccine employs a modified form of an adenovirus, whereas the other two permitted vaccines use messenger RNA technology.
The shot has proven to be effective in reaching out to hard-to-reach individuals and locations in the United States, such as the homeless and inmates of correctional facilities. The vaccine can also be kept and transported at greater temperatures than mRNA vaccines, making it more suitable for usage in low- and medium- income nations.
Be the first to comment